I hope he does find a vacated district. Because if he doesn't, the other primary candidate will just ignore him, like Stephen Lynch did. I don't believe Lynch even acknowledged John's pathetic existence. (This will not happen in Massachusetts. John would have to leave the state to find somewhere to lose while even being noticed.)
The only districts near John are Stephen Lynch who he has lost to twice,
District 7, Rep. Ayanna Pressley, D who would absolutey destroy John head to head, and
District 4 Rep. Jake Auchincloss, D . Jake Auchincloss pulled 97% of the vote in the lat election.
Kermit wants you to believe Frank's doctor could not tell that he is a troon.
That is because troonery is harmful to your health Kermit.
"One of the best-known risks associated with estrogen use in males is infertility. In their new review, Schwartz et al. note that while some patients retain limited sperm production, many do not—and they exhibit “testicular atrophy, hyalinization, and fibrosis,” meaning shrinkage, scarring, and tissue changes that may signal elevated cancer risk. A recent systematic review cited in the paper found that taking estrogen alongside testosterone blockers was linked to “higher proportions of sperm abnormalities . . . or azoospermia” (complete loss of sperm). Some of these effects may be reversible, but others are not. Tissue studies following orchiectomies (surgical removal of the testes) show widespread damage.
Cardiovascular complications are another well-documented concern. Multiple studies cited in the review report higher rates of dangerous blood clots—known as venous thromboembolism (VTE)—and strokes among trans-identifying males taking estrogen. One meta-analysis found VTE incidence more than twice as high as in non-trans-identifying males. A cohort study showed that after two years of estrogen use, the risk of VTE was over five times higher; after six years, the risk of ischemic stroke was nearly ten times higher than in non-trans-identifying males. While some research suggests that transdermal estrogen (patches or creams) may carry a lower clotting risk than oral forms (pills), all delivery methods appear to elevate cardiovascular risk.
The paper also highlights potential cognitive risks, including memory loss and early-onset impairment. While short-term studies haven’t consistently shown problems, longer-term research on older transgender-identifying males taking hormones has found poorer performance on tasks involving memory and processing speed. In postmenopausal women, estrogen use has already been linked to a doubled relative risk of dementia—an effect that appears to extend to trans-identifying males. Survey data likewise show that trans- and nonbinary-identifying adults over 45 report more cognitive difficulties than their non-trans-identifying peers.
Perhaps the most alarming finding cited in the paper is the increased risk of early death. Schwartz and colleagues reference a Dutch cohort study of patients treated at a major gender identity clinic, which found that “the overall mortality risk of [trans-identifying men] . . . was higher compared to men in the general population . . . and even higher compared to women.” Leading causes of death included heart disease, cancer, and suicide. An
earlier study found a 51 percent higher mortality rate in trans-identifying males than the general population. Notably, current estrogen use, rather than past use, was linked to these increased risks, suggesting long-term exposure to feminizing hormones may amplify health risks over time.
Beyond these headline findings, the paper outlines several additional risks. Autoimmune diseases such as lupus and systemic sclerosis have occasionally appeared or worsened following the initiation of estrogen therapy. One patient with a skin-limited autoimmune condition developed life-threatening kidney complications after starting hormones. At the population level, males with gender identity disorders have been found to have a more than sixfold increased risk of developing multiple sclerosis—raising the possibility that estrogen may act as a trigger for autoimmune responses in some individuals.
Estrogen also appears to affect metabolism. Hormone therapy has been associated with increased fat mass, muscle loss, and reduced insulin sensitivity—an early warning sign for diabetes. In one study, insulin resistance rose by more than 80 percent over two years of use. Elevated triglycerides—a type of fat in the blood—have been linked to serious complications in trans-identifying males, including pancreatitis and gallstones.
The authors also review cancer risks. Trans-identifying males on estrogen are significantly more likely to develop breast cancer than non-trans-identifying men. One cited analysis estimated the risk to be 22 to 40 times higher. While breast cancer remains rare in men overall, such increases are noteworthy.
The paper also highlights elevated rates of thyroid and testicular cancers among trans-identifying males on estrogen. Some studies suggest a potential link between testicular cancer and long-term use of estrogen or testosterone blockers. Public drug safety databases in the U.S. and France reflect similar concerns, listing tumors, cardiovascular complications, and brain tumors—such as meningiomas—among the most frequently reported adverse events.
One especially unsettling section explores how estrogen may affect the male brain. A few small brain-imaging studies found that several months of estrogen use led to “an increase in ventricular volume and a decrease in brain volume.” Studies in male rats showed similar effects: estrogen and testosterone blockers reduced brain volume and altered brain chemistry. The authors suggest these changes may result from disruptions in how water is regulated in brain cells—potentially mimicking patterns seen in degenerative diseases.
The paper also notes that levels of BDNF—a brain chemical critical for mood and memory—tend to decline in patients on cross-sex hormones. Low BDNF is associated with depression and shrinkage of the hippocampus, a brain region essential for memory. Taken together, these findings raise the possibility that estrogen may produce lasting changes in male brain structure and function."
Documented Health Risk of Male Estrogen Use
